UBS Cuts Price Target on Celyad SA (CYAD) to $79 Following 1H15

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to UBS Cuts Price Target on Celyad SA (CYAD) to $79 Following 1H15

Celyad Reports First Half 2015 Financial Results and Operational Progress

August 25, 2015 1:04 AM EDT

MONT-SAINT-GUIBERT, Belgium, Aug. 25, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2015 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2015 consolidated financial statements were subject to a limited review by the company's statutory auditors.

OPERATIONAL HIGHLIGHTS

Clinical... More

Celyad Reports First Half 2015 Financial Results and Operational Progress

August 25, 2015 1:04 AM EDT

MONT-SAINT-GUIBERT, Belgium, Aug. 25, 2015 (GLOBE NEWSWIRE) -- Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2015 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2015 consolidated financial statements were subject to a limited review by the company's statutory auditors.

OPERATIONAL HIGHLIGHTS

Clinical... More

Celyad Reports First Half 2015 Financial Results and Operational Progress

August 25, 2015 1:00 AM EDT

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD) (Paris: CYAD) (Brussels: CYAD), a leader in the discovery and development of engineered cell therapies, today announced its consolidated financial results for the six-month period ending 30 June 2015 prepared in accordance with IFRS as endorsed by the European Union. The full interim financial report (regulated information) is available on our website in the Investors section. The Half Year 2015 consolidated financial statements were subject to a limited review by the companys statutory auditors.

... More